drugset / Trial / NCT05549037

Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC

NCT05549037

Phase 3 Completed 210 enrolled Hunan Province Tumor Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to explore time-of-day of administration of immunochemotherapy on the efficacy for treatment naive advanced non-small cell lung cancer.

Timeline

Start
2022-09-23
Primary completion
2024-12-02
Completion
2026-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody
Subject Sintilimab Monoclonal antibody